#EVAX

StockTitan

@stocktitan.net

1 week ago

Evaxion announces business update and full year 2025 financial results COPENHAGEN, Denmark, March 5, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, provides business update and announces full year 2025 financial results. Business highlights 2025 was a

#EVAX Evaxion announces business update and full year 2025 financial results

www.stocktitan.net/news/EVAX/evaxion-announ...

StockTitan

@stocktitan.net

1 week ago

Evaxion plans to file 2025 annual report later today Evaxion (NASDAQ: EVAX) will slightly delay filing its 2025 annual report originally planned for Nasdaq opening on March 5, 2026, due to unforeseen technical issues with external vendors related to regulatory filing demands.The report is finalized and will be filed and published as soon as possible; the investor conference call/webcast is rescheduled to March 6, 2026 at 8:30 ET / 14:30 CET.

#EVAX Evaxion plans to file 2025 annual report later today

www.stocktitan.net/news/EVAX/evaxion-plans-...

StockTitan

@stocktitan.net

1 week ago

Evaxion to announce business update and full year 2025 financial results on March 5, 2026 Evaxion (NASDAQ: EVAX) will provide a business update and report its full year 2025 financial results on March 5, 2026 before Nasdaq opening. Executive Management will host a conference call and webcast at 14:30 CET / 08:30 EST.Registration is required to join the call for dial-in numbers and PIN; the webcast will be accessible live and a recording will be posted on the company website shortly after the event.

#EVAX Evaxion to announce business update and full year 2025 financial results on March 5, 2026

www.stocktitan.net/news/EVAX/evaxion-to-ann...

PRISM MarketView

@prismmarketview.bsky.social

2 months ago

Evaxion Expands AI-Immunology™ Platform into Autoimmune Diseases, Outlines 2026 Milestones Evaxion A/S (Nasdaq: EVAX) announced a strategic expansion of its proprietary AI-Immunology™ platform to include autoimmune disease research and discovery, po

Evaxion #EVAX Expands AI-Immunology™ Platform into Autoimmune Diseases, Outlines 2026 Milestones
prismmarketview.com/evaxion-expa...

StockTitan

@stocktitan.net

2 months ago

Evaxion expands AI-Immunology™ platform into autoimmune diseases Evaxion (NASDAQ: EVAX) is expanding its proprietary AI-Immunology™ platform to include autoimmune diseases, adding a third core disease area alongside cancer and infectious disease.The company plans to expand and train the platform for autoimmune applications in the second half of 2026. Evaxion says this work is included in its cashflow outlook and does not change cash runway, which extends into the second half of 2027. The move aims to increase program quantity and partnership potential.Key 2026 milestones target H1 and H2 events, including additional EVX-01 biomarker data, EVX-01 three-year phase 2 efficacy data (H2), a regulatory filing for EVX-04 phase 1 (H2), and EVX-B4 antigen design and preclinical validation (H2).

#EVAX Evaxion expands AI-Immunology™ platform into autoimmune diseases

www.stocktitan.net/news/EVAX/evaxion-expand...

Navia Tortu Ofertas

@navia-offers.bsky.social

2 months ago

🐢🛍️ Evax Salvaslip Normal, 50 unidades, Protección,... Antes: 2.79€ Ahora: 2.45€ 💰 -12%

🐢🛍️ Evax Salvaslip Normal, 50 unidades, Protección,...
Antes: 2.79€
Ahora: 2.45€
💰 -12%
www.amazon.es/dp/B00XAH04X8

📱 Telegram: https://t.me/TortuChollosOfertas

#Ofertas #Offers #Ofertitas #Chollos #Descuento #Amazon #AmazonPrime #AmazonEspaña #AmazonOffers #evax

StockTitan

@stocktitan.net

2 months ago

Evaxion provides update on MSD collaboration - retains global rights to Gonorrhea vaccine candidate EVX-B2 Evaxion (NASDAQ: EVAX) announced on December 19, 2025 that MSD will not exercise its option to develop the protein-based version of Evaxion’s Gonorrhea vaccine candidate EVX-B2, allowing Evaxion to retain global rights and seek a new licensing partner.Evaxion noted preclinical studies show EVX-B2 protects against Gonorrhea and that MSD earlier exercised an option on a separate candidate, EVX-B3, for which Evaxion is eligible for up to $592 million in milestones plus royalties. Evaxion said the MSD decision does not affect its cash runway, which extends to the second half of 2027. Evaxion is also developing an mRNA version of EVX-B2 with Afrigen Biologics.

#EVAX Evaxion provides update on MSD collaboration - retains global rights to Gonorrhea vaccine candidate EVX-B2

www.stocktitan.net/news/EVAX/evaxion-provid...

StockTitan

@stocktitan.net

3 months ago

Evaxion presents new data for EVX-04, a cancer vaccine candidate for acute myeloid leukemia at ASH Annual Meeting Evaxion (NASDAQ: EVAX) presented new preclinical data for its AML vaccine candidate EVX-04 at the ASH Annual Meeting on December 6, 2025. Using the company's AI-Immunology™ platform and AML patient sequencing data, EVX-04 comprises 16 ERV antigen fragments selected from ~5 million fragments for cross-patient relevance and immunogenic potential.In preclinical tumor models, EVX-04 induced strong, specific T-cell responses and prevented tumor growth. The program is positioned as an off-the-shelf therapeutic vaccine intended for immediate administration after diagnosis and described as broadly applicable to other cancers where conserved immunogenic ERV antigens are found.

#EVAX Evaxion presents new data for EVX-04, a cancer vaccine candidate for acute myeloid leukemia at ASH Annual Meeting

www.stocktitan.net/news/EVAX/evaxion-presen...

StockTitan

@stocktitan.net

3 months ago

#EVAX Evaxion announces positive data for lead antigens in cytomegalovirus (CMV) vaccine program EVX-V1

www.stocktitan.net/news/EVAX/evaxion-announ...

StockTitan

@stocktitan.net

4 months ago

Evaxion announce 2026 financial calendar Evaxion (NASDAQ: EVAX) announced its 2026 financial calendar on November 12, 2025. Key scheduled dates include:March 5, 2026 – Business update and full year 2025 financial resultsApril 16, 2026 – Annual General MeetingMay 7, 2026 – Business update and Q1 2026 financial resultsAugust 20, 2026 – Business update and Q2 2026 financial resultsNovember 19, 2026 – Business update and Q3 2026 financial resultsThe company said the full calendar is available on its website and provided investor relations contact details.

#EVAX Evaxion announce 2026 financial calendar

www.stocktitan.net/news/EVAX/evaxion-announ...

StockTitan

@stocktitan.net

4 months ago

Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 Evaxion (NASDAQ: EVAX) presented new biomarker and immune data for its AI-designed personalized cancer vaccine EVX-01 at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting on November 7, 2025.Data from the phase 2 trial—conducted in combination with Merck's anti-PD-1 therapy KEYTRUDA—report longitudinal blood sampling that characterized circulating T-cell subsets before, during and after treatment. In analyzed patient subsets, clinical responses were accompanied by a rapid and sustained induction of EVX-01-specific T cells. The release complements previously presented two-year clinical efficacy data from the same trial.

#EVAX Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01

www.stocktitan.net/news/EVAX/evaxion-presen...

StockTitan

@stocktitan.net

4 months ago

Evaxion announces business update and third quarter 2025 financial results Evaxion (NASDAQ: EVAX) reported Q3 2025 results and a business update on November 6, 2025. Key clinical and corporate highlights include appointment of Dr Helen Tayton-Martin as CEO effective Nov 24, 2025, presentation of two‑year phase 2 data for personalized cancer vaccine EVX‑01 showing a 75% ORR (12/16) with four complete responses and 92% still responding at two years, and out‑licensing of bacterial vaccine EVX‑B3 to MSD with a $7.5M option fee and potential future payments up to $592M. Financially, Q3 revenue was $7.5M, net income $4.6M, cash of $10.6M as of Sep 30, 2025, and cash runway extended to the second half of 2027.

#EVAX Evaxion announces business update and third quarter 2025 financial results

www.stocktitan.net/news/EVAX/evaxion-announ...

StockTitan

@stocktitan.net

4 months ago

#EVAX Evaxion expands R&D pipeline with new AI-designed precision cancer vaccine candidate

www.stocktitan.net/news/EVAX/evaxion-expand...

StockTitan

@stocktitan.net

4 months ago

Evaxion raises $7.2 million, extending cash runway to second half of 2027 Evaxion (NASDAQ: EVAX) raised $7.2 million through an at-the-market share sale ($4.5M) and investor warrant exercises ($2.7M), and reports a total cash inflow of $14.7M since the end of Q2 2025. Combined with a $7.5M license payment from MSD for EVX-B3 in September 2025, Evaxion says it now has cash to fund operations and R&D into the second half of 2027 (extended from H1 2027).The company reports an expected operational cash spend of $14M in 2025, a reduction of outstanding warrants by 1.0M to 2.8M total, and a weighted average warrant exercise price of $10.94. A debt-to-equity conversion reduced prior debt by $4.1M.

#EVAX Evaxion raises $7.2 million, extending cash runway to second half of 2027

www.stocktitan.net/news/EVAX/evaxion-raises...

StockTitan

@stocktitan.net

4 months ago

Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01 Evaxion (NASDAQ: EVAX) reported two-year phase 2 results for its AI-designed personalized cancer vaccine EVX-01 in advanced melanoma on October 17, 2025.Key outcomes: ORR 75% (12/16 patients), including 4 complete responses; 92% of patients still responding at 24 months; tumor reduction in 15/16 patients; 81% of vaccine targets induced T-cell responses; 54% experienced deepened responses; treatment was well tolerated. Data presented at ESMO 2025; webinar scheduled October 22, 2025.

#EVAX Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01

www.stocktitan.net/news/EVAX/evaxion-report...

Market Wire News

@marketwirenews.com

5 months ago

JUST IN: ( NASDAQ: #EVAX ) Growth Bets Drive Market Pulse Ahead of Earnings

Small Cap Strategist

@smcapstrategist.bsky.social

5 months ago

Most searched small-cap stocks, Thu Sept 25th - #EOSE #BTBT #LAES #HTXZ #RR #BB #RXRX #HIVE #ONDS #BITF #EVAX #SPRC #DNN #PLUG #PEPG #SBET #QUBT #LAC #IMRX #AEO - More: crystalequityresearch.com/most-searche... - #smallcap

Small Cap Strategist

@smcapstrategist.bsky.social

5 months ago

Small-cap stocks with improving money flow, Thu Sept 25th - #SLI #LCTX #XMTR #VECO #TLS #SEPN #PPSI #ONDS #MASS #IRD #EVAX #IBO #DXLG #CLRB #BTOC #AENT #VOC #SBR #OWLT #INVX #DQ #AMBC - More: crystalequityresearch.com/leading-indi... - #smallcap

StockTitan

@stocktitan.net

5 months ago

Evaxion out-licenses vaccine candidate EVX-B3 to MSD Evaxion (NASDAQ: EVAX) has successfully out-licensed its vaccine candidate EVX-B3 to MSD (Merck) in a significant deal worth up to $592 million plus royalties. The agreement includes an immediate $7.5 million cash payment, extending Evaxion's cash runway to H1 2027.MSD will take full responsibility for EVX-B3's development, which targets a pathogen associated with serious medical complications and currently has no available vaccines. The deal validates Evaxion's AI-Immunology™ platform technology.Additionally, MSD has extended its evaluation period for a second vaccine candidate, EVX-B2 (targeting Gonorrhea), with a licensing decision expected in H1 2026. If exercised, this option would bring an additional $2.5 million upfront payment plus similar milestone payments and royalties.

#EVAX Evaxion out-licenses vaccine candidate EVX-B3 to MSD

www.stocktitan.net/news/EVAX/evaxion-out-li...

StockTitan

@stocktitan.net

7 months ago

Evaxion announces business update and second quarter 2025 financial results Evaxion (NASDAQ: EVAX), a clinical-stage TechBio company, reported Q2 2025 financial results and business updates. Key highlights include completion of EVX-01 phase 2 trial treatments, with full two-year clinical efficacy data to be presented at ESMO Congress in October 2025. The company received recognition through a Gates Foundation grant for polio vaccine development and expanded its pipeline with EVX-B4 for Group A Streptococcus.Financial position improved with $14.7 million in cash as of June 30, 2025, sufficient until mid-2026. The company converted €3.5 million of EIB debt to equity at a 89% premium. Q2 2025 resulted in a net loss of $4.8 million ($0.02 per share), compared to $6.2 million loss in Q2 2024. R&D expenses decreased to $2.2 million from $2.8 million year-over-year.

#EVAX Evaxion announces business update and second quarter 2025 financial results

www.stocktitan.net/news/EVAX/evaxion-announ...

StockTitan

@stocktitan.net

7 months ago

Evaxion to announce business update and second quarter 2025 financial results on August 14, 2025 COPENHAGEN, Denmark, August 11, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its second quarter 2025 financial results on Thursday August 14, 2025, before opening

#EVAX Evaxion to announce business update and second quarter 2025 financial results on August 14, 2025

www.stocktitan.net/news/EVAX/evaxion-to-ann...

Small Cap Strategist

@smcapstrategist.bsky.social

7 months ago

Small-cap stocks in new uptrend with AROON Oscillator - #OBIO #PDFS #SPWH #TCBK #UPLD #WVE #ZNTL #ACCO #BORR #DEC #EAI #FF #KRP #PRO #QUAD #RIG #SES #NESR #MFIN #LGHL #KYTX #IMMP #FATE #EVAX #DAKT #BAND #AOB - More: crystalequityresearch.com/ieading-indi... - #smallcap